Shattuck Labs Inc (STTK) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.01 (+2.73%), Market cap $0.48B, 52-week low–high $0.73 ~ $7.88.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an onc
Financial statements, price targets, institutional (13F) holdings and related news for Shattuck Labs Inc are updated in real time on BlackAll Trade.
Shattuck Labs Inc trades at $6.01 (+2.73%). Real-time quotes and charts are available on BlackAll Trade.
Shattuck Labs Inc has a market cap of about $0.48B.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company d